Williams David Michael sold $6.8M of MRK

Halozyme reported Q3 2026 revenue of $493M, up 39% YoY, with adjusted EBITDA rising 35% to $336.2M. The company raised full-year guidance and won a patent case against Merck in Europe, blocking Merck's Keytruda QLEX in eight markets. Royalty revenue surged 44% to $341M, driven by strong performance across multiple products.

Merck has initiated a Phase 3 trial (ENHANCE-3) for ensifentrine (Ohtuvayre), evaluating its efficacy in reducing COPD exacerbations. The global study will enroll 2,136 patients across 28 countries. Ohtuvayre, approved by the FDA in June 2024, is a dual-action inhaled therapy for COPD maintenance.

Merck reported that its dual GLP-1/glucagon agonist drug cleared a mid-stage trial for liver disease MASH, sharing biopsy data. The drug was licensed from South Korea's Hanmi.

Merck (MRK) reported Q3 2026 sales of $18.09B, up 4.7% YoY, but net income fell 12.4% to $5.07B. EPS declined 12.1% to $2.04. The company received U.S. approvals for Lipfendra and Idvynso, expanded Keytruda indications, and acquired Terns, Cidara, and TARGAN.

Lonza has agreed to acquire Merck KGaA's U.S. contract manufacturing network for CHF 100-600M, expanding its U.S. footprint from 4 to 9 sites and adding 1,100 employees. The deal aims to meet North American demand for advanced therapies and reduce supply chain risks. Lonza expects the acquired network to generate CHF 250M in annual sales by 2028, with margins improving by the mid-2030s.

Merck invests 300 million euros ($338 million) in a new biopharmaceutical production center in Daejeon, Korea, its largest life science investment in Asia-Pacific. The move supports its 'in-region, for-region' strategy, aiming to reduce reliance on US and European sites and tap Asia's growing biotech market, according to CEO Jean-Charles Wirth. The facility is expected to create 300 jobs by 2028 and may expand based on demand.